You are here: Industry Insights > cipla

News List

Mumbai, Thane to get 60 per cent of Maharashtra’s remdesivir stock expresspharma
July 14, 2020
It is likely that Cipla and Hetero Healthcare will supply 9000 vials and 12500 vials of remdesivir, respectively, to the State this week.
Cipla launches Cipremi, likely to price it Rs 4,000 per vial expresspharma
July 09, 2020
Cipla has launched its generic version of broad-spectrum anti-viral drug remdesivir (branded Cipremi), to treat severe infection of COVID-19.
Cipla and Boehringer Ingelheim to co-market three oral anti-diabetic drugs expresspharma
June 30, 2020
The two companies will help co-market three anti-diabetic drugs Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin).
Cipla to price remdesivir version for COVID-19 under 5,000 rupees expresspharma
June 24, 2020
Indian drugmaker Cipla will price its generic version of Gilead Sciences’s antiviral drug remdesivir for use in COVID-19 patients at less than 5,000 rupees ($66), the company said.
Maha govt plans to procure 10000 vials of remdesivir from Cipla expresspharma
June 22, 2020
The Maharashtra State Government is planning to procure around 10,000 vials of remdesivir from Cipla.
Cipla launches remdesivir under brand name CIPREMI expresspharma
June 22, 2020
The product will be in the form of lyophilised powder for injection 100 mg.
Cipla and Roche partner up to improve access to oncology medicines expresspharma
June 19, 2020
Roche and Cipla had previously entered into a similar agreement in February 2018 for promotion and distribution of Tocilizumab (Actemra) and other products.
Cipla acquires stake in GoApptiv expresspharma
June 10, 2020
The acquisition of 21.85 per cent stake on a fully diluted basis will be completed in two stages.
Cipla Receives Final Approval for Generic Version Migranal americanpharmaceuticalreview
May 26, 2020
Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Dihydroergotamine Mesylate Nasal Spray 4mg/mL from the United States Food and Drug Administration (FDA) with a Competitive Generic Therapy (CGT) designation.
Cipla receives final approval for generic version of Migranal with a Competitive Generic Therapy Des expresspharma
May 21, 2020
Cipla is the “first approved applicant” for such CGT and, is therefore, eligible for 180 days of CGT exclusivity which will begin to run from the commercial marketing of Cipla’s product.

Previous page 1 2 3 4 5 6 7 8 Next page